- Home
- RDHL vs XBIO Comparison
RDHL vs XBIO Comparison
Compare RDHL & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- XBIO
- Stock Information
- Founded
- RDHL 2009
- XBIO N/A
- Country
- RDHL Israel
- XBIO United States
- Employees
- RDHL N/A
- XBIO N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- XBIO Health Care
- Exchange
- RDHL Nasdaq
- XBIO Nasdaq
- Market Cap
- RDHL 3.8M
- XBIO 4.2M
- IPO Year
- RDHL N/A
- XBIO N/A
- Fundamental
- Price
- RDHL $1.85
- XBIO $3.53
- Analyst Decision
- RDHL
- XBIO Hold
- Analyst Count
- RDHL 0
- XBIO 1
- Target Price
- RDHL N/A
- XBIO N/A
- AVG Volume (30 Days)
- RDHL 18.5K
- XBIO 169.6K
- Earning Date
- RDHL 04-10-2025
- XBIO 08-12-2025
- Dividend Yield
- RDHL N/A
- XBIO N/A
- EPS Growth
- RDHL N/A
- XBIO N/A
- EPS
- RDHL N/A
- XBIO N/A
- Revenue
- RDHL $8,042,999.00
- XBIO $2,582,728.00
- Revenue This Year
- RDHL $381.91
- XBIO $14.23
- Revenue Next Year
- RDHL N/A
- XBIO $7.14
- P/E Ratio
- RDHL N/A
- XBIO N/A
- Revenue Growth
- RDHL 23.17
- XBIO 5.63
- 52 Week Low
- RDHL $1.71
- XBIO $2.20
- 52 Week High
- RDHL $20.28
- XBIO $5.27
- Technical
- Relative Strength Index (RSI)
- RDHL 43.03
- XBIO 58.63
- Support Level
- RDHL $1.72
- XBIO $2.65
- Resistance Level
- RDHL $2.08
- XBIO $5.27
- Average True Range (ATR)
- RDHL 0.09
- XBIO 0.45
- MACD
- RDHL 0.01
- XBIO 0.09
- Stochastic Oscillator
- RDHL 27.78
- XBIO 33.61
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.